ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$8.89 USD
+0.15 (1.72%)
Updated May 13, 2024 04:00 PM ET
After-Market: $8.89 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
ARS Pharmaceuticals, Inc. [SPRY]
Reports for Purchase
Showing records 1 - 20 ( 40 total )
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Investor Day Underscores Unmet Need for No-Needle Epi; NDA Resubmission in Q2
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Repeat Dose NAC Data Addresses FDA Requests; Submission to FDA in Q2
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
AAAAI 2024: New Results from Urticaria Anaphylaxis Efficacy Studies for neffy
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2024 Outlook on Covered Companies Takeaways from Annual SF Biotech Meetings
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3: U.S./EU Approval Timelines; Market Opportunity Intact Per Post-CRL Survey
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Still a Clear Path to Approval: Repeat Dose NAC Study Sole Gating Factor
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Surprise CRL Announcement at the 11th Hour Deals Major Blow to neffy Approval
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2:23 Financials; All Eyes on Sept. 19 PDUFA Commercial Opportunity for neffy
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
neffy PDUFA Now Sept. 19; Likelihood of Approval Opportunity Remain
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A